Retransplant- and Bronchiolitis Obliterans Syndrome-Free Survival among COVID Lung Transplant Recipients: A National Cohort Study
In this national cohort study, there was no significant difference in overall and retransplant-free survival for COVID LTR compared to non-COVID, restrictive lung disease LTR at a median follow-up time of 2.5 years. COVID LTR, however, had slightly lower hazard for BOS- and retransplant-free survival.
Authors
- Joshua M. Diamond (ORCID: https://orcid.org/0000-0002-3695-4637)
- Hilary J. Goldberg (ORCID: https://orcid.org/0000-0002-2319-0009)
- Andrew Courtwright (ORCID: https://orcid.org/0000-0001-9511-5975)
Institutions
- Brigham and Women's Hospital (US)
- Hospital of the University of Pennsylvania (US)
- GlaxoSmithKline (United States) (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of the American Thoracic Society
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1513/annalsats.202508-862oc
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00